Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

yttrium Y 90-edotreotide

A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:90Y-DOTA-3-Tyr-octreotide
Y90-DOTA-tyr3-octreotide
yttrium Y 90 -DOTATOC
yttrium Y 90 SMT 487
yttrium Y 90-DOTA-3-tyrosine-octreotide
US brand name:OctreoTher
Onalta
Y-90 OctreoTher
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search